MBRX — Moleculin Biotech, Inc.

Is MBRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Moleculin Biotech, Inc. (MBRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $7.14. The rating moved from Neutral to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Moleculin Biotech, Inc. is a clinical-stage biotech with episodic upside tied to trial readouts and potential partnerships but currently lacks commercial revenue and faces meaningful financing and execution risk. Given limited social sentiment data and sector flows favoring larger, defensive pharma names, near-term movement is likely to be volatility-driven around program milestones.

Key factors

  • Clinical-stage pipeline with oncology (WP1066, Annamycin) and antiviral programs that can drive episodic, high-impact upside on positive data readouts
  • Limited or no commercial revenue; company viability depends on successful trials, partnerships, or external financing
  • Cash runway and financing profile exposed to dilution risk given sector trend toward convertible-debt financings and mid-cap biotech capital needs
  • Regulatory and clinical readouts remain the primary near-term catalysts and value drivers
  • Current market environment favors large-cap pharma defensives, reducing speculative demand for small-cap biotech absent clear catalysts
  • Potential for partnership or licensing transactions that could de-risk programs and provide non-dilutive funding

Risks

  • Clinical trial failure or unfavorable safety/efficacy data for lead programs, which would materially compress valuation
  • Need for additional capital leading to dilution (equity or convertible instruments) that could depress share price
  • Regulatory setbacks or slower-than-expected enrollment and timelines for pivotal studies
  • Competitive advances in oncology and antiviral spaces that reduce addressable market or make programs less differentiated
  • Low liquidity and limited institutional coverage, amplifying volatility on news events
  • Macro/sector rotations favoring large-cap pharma could limit rebounds absent company-specific positive news

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MBRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.